Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice
- PMID: 28500865
- DOI: 10.1016/j.atherosclerosis.2017.05.003
Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice
Abstract
Background and aims: Dihydromyricetin, the most abundant flavonoid in Ampelopsis grossedentata, exerts numerous pharmacological activities, including anti-inflammatory, antioxidant, hepatoprotective, and lipid regulatory activities; however, its protective effect against atherosclerosis remains poorly understood. The aim of the present study was to evaluate the effects of dihydromyricetin on high fat diet (HFD)-induced atherosclerosis using LDL receptor deficient (LDLr-/-) mice.
Methods: Blood samples were collected for determination of serum lipid profiles, oxidized LDL (ox-LDL) and pro-inflammatory cytokines. Histology, hepatic lipid content, quantification of atherosclerosis, assessment of oxidative stress and inflammation were performed on liver and aorta samples by molecular biology methods. The effects of dihydromyricetin on ox-LDL-induced human umbilical vein endothelial cells (HUVECs) dysfunction and foam cell formation were further studied.
Results: (1) Dihydromyricetin ameliorated hyperlipidemia, reduced serum ox-LDL, IL-6 and TNF-α levels in HFD-fed LDLr-/- mice. Moreover, (2) dihydromyricetin suppressed hepatic lipid accumulation and increased protein expressions of PPARα, LXRα and ABCA1. (3) It inhibited atherosclerotic lesion formation and favoured features of plaque stability. (4) Dihydromyricetin prevented hepatic and aortic inflammation as evidenced by the reduced IL-6 and TNF-α mRNA expression; (5) it prevented hepatic and aortic oxidative stress by normalizing activities of antioxidant enzymes in the liver and suppressing reactive oxygen species generation and NOX2 protein expression in both liver and aorta; (6) it inhibited oxLDL-induced injury, monocytes adhesion and oxidative stress in HUVECs and (7) inhibited macrophage foam cell formation and enhanced cholesterol efflux.
Conclusions: These findings suggest that dihydromyricetin could reduce atherosclerosis via its pleiotropic effects, including improvement of endothelial dysfunction, inhibition of macrophage foam cell formation, amelioration of lipid profiles, anti-inflammatory action and anti-oxidative effect.
Keywords: Anti-inflammation; Anti-oxidation; Atherosclerosis; Dihydromyricetin.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Ganoderma lucidum triterpenoids and polysaccharides attenuate atherosclerotic plaque in high-fat diet rabbits.Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1929-1938. doi: 10.1016/j.numecd.2021.03.023. Epub 2021 Apr 6. Nutr Metab Cardiovasc Dis. 2021. PMID: 33992512
-
Dihydromyricetin ameliorates foam cell formation via LXRα-ABCA1/ABCG1-dependent cholesterol efflux in macrophages.Biomed Pharmacother. 2018 May;101:543-552. doi: 10.1016/j.biopha.2018.02.124. Epub 2018 Mar 22. Biomed Pharmacother. 2018. PMID: 29505925
-
Longxuetongluo capsule inhibits atherosclerosis progression in high-fat diet-induced ApoE-/- mice by improving endothelial dysfunction.Atherosclerosis. 2016 Dec;255:156-163. doi: 10.1016/j.atherosclerosis.2016.08.022. Epub 2016 Aug 23. Atherosclerosis. 2016. PMID: 27591127
-
Targeting foam cell formation and macrophage polarization in atherosclerosis: The Therapeutic potential of rhubarb.Biomed Pharmacother. 2020 Sep;129:110433. doi: 10.1016/j.biopha.2020.110433. Epub 2020 Jun 28. Biomed Pharmacother. 2020. PMID: 32768936 Review.
-
Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.Verh K Acad Geneeskd Belg. 2008;70(3):193-219. Verh K Acad Geneeskd Belg. 2008. PMID: 18669160 Review.
Cited by
-
Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability.Trends Food Sci Technol. 2019 Sep;91:586-597. doi: 10.1016/j.tifs.2019.07.038. Epub 2019 Jul 25. Trends Food Sci Technol. 2019. PMID: 32288229 Free PMC article. Review.
-
Dihydromyricetin Inhibits M1 Macrophage Polarization in Atherosclerosis by Modulating miR-9-Mediated SIRT1/NF-κB Signaling Pathway.Mediators Inflamm. 2023 May 17;2023:2547588. doi: 10.1155/2023/2547588. eCollection 2023. Mediators Inflamm. 2023. PMID: 37234960 Free PMC article.
-
Dihydromyricetin Modulates Nrf2 and NF-κB Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity.Pharmaceuticals (Basel). 2023 Mar 23;16(4):481. doi: 10.3390/ph16040481. Pharmaceuticals (Basel). 2023. PMID: 37111238 Free PMC article.
-
Dihydromyricetin mitigates abdominal aortic aneurysm via transcriptional and post-transcriptional regulation of heme oxygenase-1 in vascular smooth muscle cells.Acta Pharm Sin B. 2025 Mar;15(3):1514-1534. doi: 10.1016/j.apsb.2025.02.003. Epub 2025 Feb 11. Acta Pharm Sin B. 2025. PMID: 40370559 Free PMC article.
-
Dihydromyricetin Ameliorates Cardiac Ischemia/Reperfusion Injury through Sirt3 Activation.Biomed Res Int. 2019 Apr 16;2019:6803943. doi: 10.1155/2019/6803943. eCollection 2019. Biomed Res Int. 2019. PMID: 31139646 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous